Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
This is the first evidence that Tan-Ⅰ induced apoptosis and promoted autophagy via the inactivation of PI3K/AKT/mTOR pathway on ovarian cancer and further inhibited tumour growth, which might be considered as effective strategy.
|
31820522 |
2020 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
|
31639424 |
2020 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The newly identified miR-99a/HOXA1/AKT/mTOR axis provides novel insight into the pathogenesis of ovarian cancer.
|
31210292 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken all data together, these findings demonstrated that the absence of SMURF1 repressed cell proliferation, invasive capability, and EMT process in ovarian cancer through DAB2IP/AKT/Skp2 signaling loops, suggesting that SMURF1 may serve as a new potential therapeutic agent for ovarian cancer.
|
30672020 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The addition of VEGF, IGF-1, and IL-8 weakened the inhibitory effect of DIRAS3 on ERK/AKT activity and reduced DIRAS3-mediated TFEB or FOXo3a nuclear localization and MAPLC3B expression in ovarian cancer cells.
|
30620384 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically.
|
30972187 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Evaluation of ovarian cancer risk in granulosa cells treated with steroid-depleted endometriosis serum: Role of NF-κB/RelA and AKT.
|
30515820 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas.
|
31752654 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SNHG16 may activate phosphorylation of AKT and upregulate the expression of MMP9 to promote cell proliferation, invasion and migration of ovarian cancer.
|
29461589 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance.
|
30129654 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data suggested that PI3K induced epithelial-to-mesenchymal transition and promoted cell migration and invasion by activating the PI3K/AKT pathway in ovarian cancer.
|
30245957 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer.
|
29401696 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Many studies involving patients with cisplatin-resistant ovarian cancer have shown that AKT activation leads to inhibition of apoptosis.
|
27935869 |
2017 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gene composition analyses of the disrupted modules revealed five common genes (mitogen‑activated protein kinase 1, phosphoinositide 3‑kinase‑encoding catalytic 110‑KDα, AKT serine/threonine kinase 1, cyclin D1 and tumor protein P53) across the four subtypes of ovarian cancer.
|
28983627 |
2017 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
|
25677064 |
2015 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results indicate that FAK inhibition can suppress ovarian cancer cells migration and invasion through inhibiting downstream signaling (PI3K/AKT), which might be a therapeutic target or biomarker for ovarian cancer.
|
24115647 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, VEGF expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phosphorylated AKT.
|
24815691 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
|
25176450 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, REDD1 and p-AKT over-expression may serve as a prognostic biomarker in OC, but KRAS mutations and REDD1 protein over-expression were not correlated in OC.
|
25337238 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma.
|
25216292 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
|
23246288 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The occurrence of ARID1A mutations and alterations in the PI3K/AKT pathway in endometriosis and endometriosis-associated ovarian carcinomas, as well as the possible functional and clinical implications are discussed in this review.
|
24036443 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
|
23869765 |
2013 |